Ovarian Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Women aged 19 years or older who have been diagnosed with a specific type of ovarian cancer (high-grade serous, endometrioid, clear cell, or mixed type) confirmed by a pathology test.
- People whose cancer has been classified as an advanced stage (Stage III or IV).
- People who have completed surgery to remove tumours (either before or during chemotherapy) as well as a platinum-based chemotherapy treatment — additional maintenance treatments such as bevacizumab or PARP inhibitors are also permitted.
- People whose scans or clinical assessment show no visible signs of remaining cancer after completing platinum-based chemotherapy.
- People who have provided written consent to take part in the study.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose scans show the cancer was still growing during or immediately after treatment.
- People whose expected survival is three months or less.
- People with a weakened immune system or a condition that causes abnormal bleeding.
- People who are unable to have blood tests, or who are unwilling to have blood taken multiple times during the study.
- People who currently have, or have had, another type of solid cancer tumour within the past five years.
- People who do not agree to take part in the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +82-2-3010-3646
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Relapse-Free Survival (RFS) according to ctDNA Minimal Residual Disease (MRD) status
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.